NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Fexofenadine in Patients With Active Rheumatoid Arthritis

RecruitingPhase 1, Phase 2

Sponsor: October 6 University

Conditions: Rheumatoid Arthritis

Interventions: Fexofenadine, Placebo

Countries: Egypt

Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria

* Moderate to severe RA (disease activity score-28 joints: DAS-28 \> 3.2) were recruited.
* Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
* Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.

Exclusion Criteria:

* History of biological DMARDS.
* History/presence of acute heart disease, liver and kidney diseases, COPD
* Intolerance or allergy to fexofenadine or methotrexate
* Alcohol abuse
* Any changes in using medication (changing the dosage or type of medicines
* Receive hormone replacement therapy, warfarin, and other anticoagulants

Locations (2)

Banī Suwayf, Egypt
Banī Suwayf, Egypt